Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050596 · ClinicalTrials.gov registry record · Phase 2
Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00050596: Completed Phase 2 study, sponsored by Bristol-Myers Squibb.
NCT00050596 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00050596, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The primary objectives of the study are to determine the safety and activity of multiple doses of MDX-010 in patients with hormone-refractory prostate cancer (HRPC), and to determine the safety and activity profile of a single dose of cytotoxic chemotherapy (docetaxel) in combination with MDX-010
Interventions
- DRUG MDX-010 / MDX-010 + Docetaxel
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-11 |
| Est. Completion | 2004-11 |
| Phase | Phase 2 |
What the finished NCT00050596 record still lists
NCT00050596 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which MDX-010 / MDX-010 + Docetaxel is the first listed.
NCT00050596 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00050596 about?
NCT00050596 is a clinical study titled "Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer". The primary objectives of the study are to determine the safety and activity of multiple doses of MDX-010 in patients with hormone-refractory prostate cancer (HRPC), and to determine the safety and activity profile of a single dose of cytotoxic chemotherapy (docetaxel) in combination with MDX-010
What is the current status of trial NCT00050596?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-11. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00050596?
The interventions under investigation include: MDX-010 / MDX-010 + Docetaxel (DRUG).
Who is sponsoring clinical trial NCT00050596?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia